Compare Tempus AI (TEM) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs Veritone Inc — how do they compare? Tempus AI trades at $70 (market cap $12.77B), while Veritone Inc trades at $0.61 (market cap $70.27M). The key difference: Tempus AI is far larger — about 181.7× Veritone Inc's market cap, and Tempus AI is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tempus AI for 22 Days and Veritone Inc for 12 Days on average.
| TEM | VERI | |
|---|---|---|
Market Cap | $12.77B | $70.27M |
Volume | 8,980,490 | 9,630,093 |
Sector | Broad Market / Factor | Technology |
52-Week High | $99.28 | $8.39 |
52-Week Low | $41.55 | $0.59 |
Typical Hold Time | 22 Days | 12 Days |
Enterprise Value | $13.40B | $105.66M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Veritone (VERI) trades at $0.6913, down 7.38% over 24 hours, reflecting persistent bearish technical momentum. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -117.54%, though it maintains a gross profit margin of 66.2%. Recent developments include a $15 million equity offering announced October 2026 and new partnerships, such as with ATP Media, to drive future revenue streams. Cash flow remains challenging, with negative operating cash flow offset by financing activities.
The investment outlook is highly speculative. Analyst consensus suggests significant upside with a $3.75 price target, but substantial execution risks exist. High cash burn, ongoing losses, and a securities class action investigation pose threats to shareholder value. The stock's deep value proposition hinges on successful AI solution adoption and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
